(Q41759692)

8 October 2017

title

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea (English)

1 reference

8 October 2017

1 reference

1 reference

L Ji

1

1 reference

8 October 2017

P Han

2

1 reference

8 October 2017

Y Liu

3

1 reference

8 October 2017

G Yang

4

1 reference

8 October 2017

N K Dieu Van

5

1 reference

8 October 2017

U Vijapurkar

6

1 reference

8 October 2017

R Qiu

7

1 reference

8 October 2017

G Meininger

8

1 reference

8 October 2017

language of work or name

1 reference

14 October 2014

1 reference

Diabetes, Obesity and Metabolism

8 October 2017

published in

1 reference

8 October 2017

volume

17

1 reference

8 October 2017

issue

1

1 reference

8 October 2017

page(s)

23-31

1 reference

Standards of medical care in diabetes--2013

8 October 2017

cites work

1 reference

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

21 January 2018

1 reference

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

21 January 2018

1 reference

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

21 January 2018

1 reference

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

21 January 2018

1 reference

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

21 January 2018

1 reference

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial

21 January 2018

1 reference

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

21 January 2018

1 reference

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

Prevalence of diabetes among men and women in China

21 January 2018

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12385

1 reference

release_hbwjoswdpfah3e5z6xpww7w2jq

8 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hbwjoswdpfah3e5z6xpww7w2jq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference